Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Carcinoma, Renal Cell

• Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)
• Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy
• Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
• A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
• Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma
• Study of ST-1898 in Advanced Renal Cell Carcinoma
• Advanced Diffusion Imaging in Renal Cancer Patients
• Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
• Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
• Phase I/II Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer
• Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
• Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma
• A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
• KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
• Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
• A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
• Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
• OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
• Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)
• Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal
• Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC
• A Study of RC198 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
• Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
• A Study of BPI-452080 in Subjects With Solid Tumors
• Fruquintinib and Serplulimab Combination Therapy for First-line Treatment of Non-clear Cell Renal Cell Carcinoma: A Prospective Multicenter Study
• Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR
• Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Specific Subtypes of Renal Cell Carcinoma
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
• A Bioequivalence Study of Sunitinib Malate Capsules.
• Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma
• Measuring Oncological Value of Exercise and Statin
• A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
• Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
• Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
• First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
• Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
• Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma
• A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
• PRO1160 for Advance Solid and Liquid Tumors (PRO1160-001)
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
• Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
• Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
• Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
• A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
• Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
• A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
• Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
• 68Ga-labeled NY104 PET Imaging in Patients
• Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
• A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers
• A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors
• Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma
• Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
• A Pilot Study of the Immunomodulatory Agent Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
• A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024)
• A Phase 2 Study of 6MW3211 in Patients With Advanced Clear Cell Renal Cancer
• 68Ga-P16-093 and 18F-FDG PET/CT Imaging in the Same Group of Clear Cell Renal Cell Carcinoma Patients
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
• Phase I/II Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
• Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
• A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
• Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
• Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus
• Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
• Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
• Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
• Phase II Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma
• A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)
• Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
• A Study of AK104 Plus Axitinib in Advanced/Metastatic Clear Cell Renal Cell Carcinoma
• Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
• A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
• Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
• P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
• A Study of HFB200301 in Adult Patients With Advanced Solid Tumors
• Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
• Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
• CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma
• Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors
• Avelumab, Palbociclib and Axitinib in Advanced RCC
• Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
• Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer
• Autologous Dendritic Cell Vaccine in Kidney Cancer
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
• CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
• A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
• A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
• Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors
• Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
• Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
• A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
• A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
• NeoAdjuvant Pembrolizumab and STEreotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma
• Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
• Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
• [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
• Testing of Bevacizumab, Erlotinib, and Atezolizumab for Advanced-Stage Kidney Cancer
• GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
• TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors
• A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
• Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
• REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
• Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
• DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
• A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
• A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)
• Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell R
• the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors
• Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
• A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
• Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
• Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
• Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
• Study of INCB086550 in Select Solid Tumors
• ABEMA Alone or in COMBO With MK-6482
• Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)
• Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
• Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
• Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radio
• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
• Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors
• Study to Evaluate the Safety of IMM-01 in Patients With Advanced Solid Tumours
• A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
• Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
• Anesthesia and Cancer Study: Renal Cell Carcinoma
• Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
• A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
• A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
• Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb
• A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
• Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
• Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
• Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
• Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
• DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
• Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
• Study of SRF388 in Patients With Advanced Solid Tumors
• Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
• Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
• CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
• Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
• Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
• Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
• The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma
• Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
• Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
• Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
• A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
• Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
• Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation
• Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
• Sintilimab in FH-deficient Renal Cell Carcinoma
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
• Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
• Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
• Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
• Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
• SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
• Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
• Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study
• Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma
• CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
• Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma
• A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma
• Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
• Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging
• 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
• High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
• Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
• Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial
• Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)
• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
• Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
• MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
• PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
• Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau
• A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
• SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
• High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
• A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
• A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
• Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
• TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
• CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
• Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
• Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery
• Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)
• Study of INBRX-105 in Patients With Solid Tumors
• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
• Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
• Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
• IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
• WIRE - Novel Treatments in Renal Cell Cancer
• A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carc
• A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
• PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
• ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
• Phase II Trial of AZD6738 Alone and in Combination With Olaparib
• Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma
• A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
• 9-ING-41 in Patients With Advanced Cancers
• A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.
• APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
• Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
• A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
• A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
• Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
• A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
• A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
• Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
• Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
• PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
• A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
• A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
• Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
• Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy
• Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
• Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma
• Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
• Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
• Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
• Effects of Anesthesia on Immunity in Cancer
• CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors
• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma
• High Dose IL 2 and Entinostat in RCC
• Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
• Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer
• Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma
• A Study of BCD-135 in Patients With Advanced Solid Tumors
• A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
• Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
• CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
• Study of Nivolumab for Advanced Cancers in India
• Prior Axitinib as a Determinant of Outcome of Renal Surgery
• A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
• CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma
• Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies
• A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
• Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
• Testosterone in Metastatic Renal Cell Carcinoma Patients
• BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
• caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
• A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
• Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
• A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
• Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
• Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)
• Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
• First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
• A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
• Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
• Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
• Renal Adjuvant MultiPle Arm Randomised Trial
• Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
• Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
• Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
• Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
• Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC
• A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
• Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
• A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma
• A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
• Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
• Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment
• Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
• Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
• Diagnostic Imaging for Clear Cell Renal Cell Carcinoma
• Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
• APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
• Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
• Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
• Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
• A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
• ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With Renal Cell Carcinoma (RCC)
• Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
• Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
• Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
• M8891 First in Human in Solid Tumors
• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
• Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
• Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
• A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
• Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
• PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma
• Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
• CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
• Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
• Savolitinib vs. Sunitinib in MET-driven PRCC.
• Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
• Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
• INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers
• Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
• SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients
• Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)
• APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
• Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
• A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
• Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
• Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
• Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
• Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
• A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
• Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
• Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
• Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
• A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
• Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
• Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
• A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
• Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
• Pazopanib Vs. Local Therapy for Renal Cancer With Metastases
• A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
• NeoVax Plus Ipilimumab in Renal Cell Carcinoma
• Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
• HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
• Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
• Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
• TIL Therapy for Metastatic Renal Cell Carcinoma
• Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma
• Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
• A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
• Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
• Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer
• A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
• Enzalutamide Before Surgery in Treating Patients With Kidney Cancer
• Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
• Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
• PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
• Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours
• Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
• Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
• A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
• Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
• MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
• Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
• Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)
• Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
• Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
• A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
• An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
• Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
• Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
• Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma
• Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
• Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
• Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
• A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
• Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
• Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
• Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
• TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
• Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
• Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma
• A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
• A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
• A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC
• Bevacizumab in Metastatic Renal Cancer
• A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
• Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)
• Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma
• Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
• A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients
• A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
• 18F-FSPG PET/CT for Cancer Patients on Therapy
• An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
• Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
• Study of the Combination of CM082 With Everolimus in Patients With mRCC
• A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
• Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma
• Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
• Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
• Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
• Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
• A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
• SLM + Axitinib for Clear Cell RCC
• Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
• Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
• Intraoperative Dual-modality Imaging in Renal Cell Carcinoma
• Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
• Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
• Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
• PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
• A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
• Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)
• A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
• Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
• Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation
• Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)
• Survivorship Promotion In Reducing IGF-1 Trial
• Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
• Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
• Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients With Advanced Malignancies
• Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
• A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
• Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
• A Study of rSIFN-co in Subjects With Advanced Solid Tumors
• INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
• A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
• Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
• Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
• Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
• A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
• Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
• Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
• Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer
• A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
• A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma
• Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
• Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
• A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
• Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
• Safety Study of SGN-CD70A in Cancer Patients
• A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
• Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
• Molecular Determinants for Therapy Response on Renal Cell Carcinoma
• CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
• Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
• Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
• A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors
• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
• A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
• A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
• Second Line Sorafenib After Pazopanib in Patients With RCC
• Optimizing Pazopanib Exposure in RCC Patients
• Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
• Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
• Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy
• Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）
• Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
• Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
• Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
• Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma
• A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
• Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours
• Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
• Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer
• The Intrathecal Morphine for Nephrectomy
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma
• Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma
• A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
• Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
• Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients
• High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
• Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy
• Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer
• Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
• A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
• Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy
• Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer
• Tivozanib + Gemcitabine in Metastatic RCC
• A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients
• A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
• A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
• A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
• A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer
• 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC
• Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer
• A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
• Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)
• Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
• Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
• REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
• Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma
• A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma
• Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
• A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
• Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
• Sequential Therapy in Metastatic Renal Cell Carinoma
• Sorafenib in Elderly mRCC
• Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
• Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
• Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
• Imaging Studies of Kidney Cancer Using 18F-VM4-037
• Interleukin-2 in Metastatic Kidney Cancer
• A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
• Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma
• Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma
• Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
• Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
• A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
• A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
• A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
• Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
• 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer
• Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
• Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
• CRLX101 Plus Bevacizumab in Advanced RCC
• A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
• Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
• Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
• Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes
• Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer
• Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
• Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
• Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
• Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
• Pazopanib in Second-line Therapy in Renal Cell Carcinoma
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
• Vascular Targeted Photodynamic Therapy T1a Renal Tumours
• Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
• Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
• Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
• Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
• Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
• pazopanib_NCRCC,Ph2 STUDY
• CREATE: Cross-tumoral Phase 2 With Crizotinib
• Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
• First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
• Phase II Study of Alternating Sunitinib and Temsirolimus
• Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
• Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma
• Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
• Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients
• PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
• Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
• AMG 172 First in Human Study in Patients With Kidney Cancer
• Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
• RGD-PET-CT in Cancer Angiogenesis
• Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
• Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy
• A Rollover Protocol for Subjects Previously Treated With AGS-003
• Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
• Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
• Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
• Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
• Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
• Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer
• Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
• BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
• Hepatic Monitoring for Pazopanib
• Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
• Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
• Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy
• PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
• PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
• A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
• Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
• Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
• Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
• Rotating Pazopanib and Everolimus to Avoid Resistance
• Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
• Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
• Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
• HYPAZ: Hypertension Induced by Pazopanib
• Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
• A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
• Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
• Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
• Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
• Vandetanib to Treat Advanced Kidney Cancer
• Neoadjuvant Pazopanib in Renal Cell Carcinoma
• Phase I Biomarker Study (BMS-936558)
• Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer
• Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer
• Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma
• Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
• Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
• A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
• A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
• Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
• Fluorescence Imaging in Finding Tumors in Patients With Kidney Tumors
• Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
• MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
• Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
• IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
• Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
• A Phase 1b Trial in Patients With Renal Cell Cancer
• Brivanib Metastatic Renal Cell Carcinoma
• Temsirolimus-RCC-imaging
• Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
• Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
• Cancer in Patients With Gabapentin (GPRD)
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
• Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib (SORHORM)
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
• Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
• Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
• CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
• Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
• Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
• Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
• A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
• Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
• Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
• Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
• Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
• Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
• Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
• Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
• A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
• Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
• Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
• Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
• Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
• Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
• Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
• Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
• Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer
• Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
• Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma
• A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy
• Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)
• A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
• Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
• A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
• A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer
• Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma
• Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers
• Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
• A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
• Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma
• A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
• Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers
• An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
• Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
• Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
• Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
• Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
• Efficacy of Ultrasound Contrast Agent to Assess Renal Masses
• Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
• Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
• A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Advanced Renal-Cell Carcinoma
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
• Sunitinib in Metastatic Renal Cancer
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma
• Cost Effectiveness Of Sunitinib In Central America And Caribbean
• A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
• Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
• Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
• Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
• A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma
• Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
• Regulatory Post Marketing Surveillance Study on Nexavar®
• Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
• An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma
• A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
• Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
• Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
• Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
• Sunitinib Malate in Treating Patients With Kidney Cancer
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
• A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
• Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
• Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
• A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-
• Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
• Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma)
• Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
• Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
• Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
• Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
• Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
• Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
• Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
• Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
• Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
• An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
• Study In Patients With Kidney Cancer Treated With Sutent
• Sorafenib in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Sunitinib or Bevacizumab
• DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma
• VEG111485: A QTc Study of Pazopanib
• Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
• AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
• Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
• Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
• Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
• Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
• Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal
• RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
• Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma
• Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
• A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).
• A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
• Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
• Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
• A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®
• Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
• A Phase II Study of AS1411 in Renal Cell Carcinoma
• A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
• Sequential Study to Treat Renal Cell Carcinoma
• Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
• Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
• Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)
• Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
• Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
• Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
• Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)
• A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
• A Study for Participants With Metastatic Renal Cell Carcinoma
• Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
• Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
• Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
• Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe
• Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT®
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
• A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
• Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
• Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
• Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
• A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
• Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
• BAY43-9006 Phase II Study for Renal Cell Carcinoma
• Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy
• Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)
• Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
• Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
• Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
• Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
• Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
• Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
• Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
• Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma
• Sorafenib Dose Escalation in Renal Cell Carcinoma
• Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
• Study of Sorafenib and Palliative Radiotherapy in Kidney Cancer That Spreads to the Bone
• Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
• MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
• Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
• Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens
• PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases
• Long-term Extension From RCC Phase II (11515)
• Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
• Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
• Treatment of Advanced Renal Cell Carcinoma With Quinacrine
• Study of Sunitinib Administered as 4/2 vs. 2/1 Schedule in Advanced Renal Cell Carcinoma (RCC)
• Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
• Phase II Study of Vandetanib in Individuals With Kidney Cancer
• A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
• Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
• Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
• Phase 2 Study in Patients With MiT Tumors
• Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
• Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
• The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
• LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
• Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
• Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
• A SU011248 Expanded Access Protocol for Systemic Therapy of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
• Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer
• A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma
• IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease
• Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC
• Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
• A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
• Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
• A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma
• Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
• Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
• Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC
• Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
• An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
• Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer
• A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
• Pemetrexed Plus Gemcitabine in Renal Cell Cancer
• Zoledronate With Atorvastatin in Renal Cell Carcinoma
• Talabostat in Treating Patients With Metastatic Kidney Cancer
• Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
• A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
• A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
• Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
• Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
• Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
• Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
• Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
• AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
• Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
• Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
• Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
• Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
• Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
• High-dose Bevacizumab in Advanced Renal Carcinoma Patients
• A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
• Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer
• Safety Study of RAD001 to Treat Patients With Metastatic Kidney Cancer
• Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
• Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
• Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma
• Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer
• Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
• A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
• Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
• Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
• Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma
• Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma
• A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
• A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
• A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
• ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma
• Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
• A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
• Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer
• Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
• Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
• Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
• A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
• Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer
• Perifosine + Sunitinib Malate for Patients With Advanced Cancers
• Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
• Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
• Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
• Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
• Study To Assess Long Term Safety Of Pazopanib
• Sorafenib and RAD001 Renal Cell Carcinoma
• A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
• Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
• Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
• Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
• A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
• Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
• Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
• Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
• Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
• Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
• Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
• Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
• Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
• [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
• Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
• AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
• Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
• Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
• Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery
• Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
• Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
• Vorinostat in Treating Patients With Kidney Cancer
• Study of XL999 in Patients With Metastatic Renal Cell Carcinoma
• Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma
• Bortezomib in Treating Patients With Metastatic Kidney Cancer
• Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
• A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
• Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
• Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma
• Study of SU011248 in Patients With Advanced Kidney Cancer
• GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
• Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
• Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
• A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
• Immunochemotherapy for Metastatic Renal Cell Carcinoma
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
• Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
• Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
• Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
• Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
• OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma
• Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
• Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
• Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
• Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
• Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
• Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
• Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.
• Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
• Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer
• Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
• ATN-161 in Advanced Renal Cell Cancer
• Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
• Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
• Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
• Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
• Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
• BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
• Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
• Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
• CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
• Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
• Research Study for Patients With Metastatic Renal Cell Carcinoma
• A Research Study for Patients With Metastatic Renal Cell Carcinoma
• Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
• Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
• Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)
• Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
• Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
• Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
• 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
• PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer
• Vaccine Treatment of Kidney Cancer
• SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
• Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
• 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
• SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
• Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
• A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
• Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
• A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
• Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer
• 3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
• Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
• Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
• Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma
• A Study of ABT-751 in Patients With Renal Cell Cancer
• Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma
• Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)
• Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
• Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
• A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
• S0312, Gemcitabine and Capecitabine in Treating Patients With Advanced Renal Cell (Kidney) Cancer
• ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer
• Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma
• Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
• Interferon Alfa With or Without Interleukin-2 and Fluorouracil in Treating Patients With Advanced Metastatic Kidney Cancer
• Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer
• Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer
• Erlotinib in Treating Patients With Advanced Kidney Cancer
• Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
• Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
• CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
• Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
• BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
• Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
• BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
• Study of CP-461 in Patients With Advanced Renal Cell Cancer
• Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
• Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer
• BMS 247550 to Treat Kidney Cancer
• UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer
• Biological Therapy and Chemotherapy in Treating Patients With Metastatic Kidney Cancer or Colorectal Cancer
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
• Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer
• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
• PS-341 in Treating Patients With Metastatic Kidney Cancer
• Chemotherapy in Treating Patients With Metastatic Kidney Cancer
• Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
• PS-341 in Treating Patients With Metastatic Kidney Cancer
• Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer
• ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
• ZD 1839 in Treating Patients With Metastatic Kidney Cancer
• Chemotherapy in Treating Patients With Advanced Kidney Cancer
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
• Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
• Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer
• SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
• Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
• Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer
• AE-941 in Treating Patients With Metastatic Kidney Cancer
• Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer
• Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
• Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
• Bryostatin 1 In Treating Patients With Progressive Kidney Cancer
• Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
• Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer
• Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
• Biomed 101 and Interleukin-2 in Treating Patients With Kidney Cancer
• Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
• Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
• Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer
• Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
• Combination Chemotherapy in Treating Patients With Metastatic Kidney Cancer
• Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
• Tretinoin Plus Interferon Alfa in Treating Patients With Metastatic Kidney Cancer
• Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
• Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer
• Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
• Aminocamptothecin in Treating Patients With Advanced or Recurrent Kidney Cancer
• Antineoplaston Therapy in Treating Patients With Stage IV Kidney Cancer
• 6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
• Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer
• Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
• Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
• Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
• A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer
• A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
• A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833